Background: Antiallergic effect of 20(S)-protopanaxatriol (PPT), an intestinal metabolite of ginseng saponins, was investigated in guinea pig lung mast cells and mouse bone marrow-derived mast cells activated by a specific antigen/antibody reaction. Methods: Increasing concentrations of PPT were pretreated 5 min prior to antigen stimulation, and various inflammatory mediator releases and their relevant cellular signaling events were measured in those cells. Results: PPT dose-dependently reduced the release of histamine and leukotrienes in both types of mast cells. Especially, in activated bone marrow-derived mast cells, PPT inhibited the expression of Syk protein, cytokine mRNA, cyclooxygenase-1/2, and phospholipase A 2 (PLA 2 ), as well as the activities of various protein kinase C isoforms, mitogen-activated protein kinases, PLA 2 , and transcription factors (nuclear factor-kB and activator protein-1). Conclusion: PPT reduces the release of inflammatory mediators via inhibiting multiple cellular signaling pathways comprising the Ca 2þ influx, protein kinase C, and PLA 2 , which are propagated by Syk activation upon allergic stimulation of mast cells.
Introduction
It has been reported that Panax ginseng Meyer exerts a variety of pharmacological effects on the immune system [1] . In the studies with human and rodents, ginseng extracts or various ginseng components exhibited mitogenic activity on T and B lymphocytes [2, 3] , and immunomodulatory effects in a variety of diseases [4, 5] . Ginseng saponin enhances the phagocytic activity of macrophage by increasing the intracellular Ca 2þ level ([Ca 2þ ] i )and the protein kinase C activity [6] , and ginsenoside Rh1 inhibits cyclooxygenase-2 (COX-2) expression and nuclear factor (NF)-kB activation [7] . However, a person engaged in Korean ginseng wholesale was recently reported to be suffering from occupational asthma [8] .
In the inflammatory and allergic responses, protopanaxadiol Rb1 inhibits histamine release and leukotrienes (LTs) in guinea pig lung mast cells (GPMCs) activated by specific antigen/antibody reaction [9] . Ginseng ameliorates chronic histopathologic changes in murine asthma [10] . Ginsan, a polysaccharide derived from P. ginseng, also has tumoricidal activities [11] , antiseptic activity [12] , and antiasthmatic effects in a mouse OVA (ovalbumin)-induced asthma model [13] .
A variety of ginseng saponin metabolites are formed by intestinal bacteria when total ginseng extracts or total ginseng saponin is administered orally to a human or rat, respectively, and absorbed into the systemic circulation [14, 15] , and then their metabolites including nonsugar moieties of ginsenosides (aglycones) are detected in blood and in urine. Compound K [16] and Rh2 [17] among various ginseng metabolites have potent inhibitory activity on b-hexosaminidase release from RBL-2H3 cells.
Mast cells are well known as major effector cells for immunoglobulin (Ig) E-mediated immediate hypersensitivity and chronic allergic reactions such as asthma. Antigen-specific IgE bound to the high-affinity receptor (FceRI) on the mast cell membrane encounters the multivalent antigen, and then the cells are activated. Activated mast cells secrete preformed mediators [histamine, tryptase, chymase, tumor necrosis factor (TNF)a, and other proteins] as well as newly synthesized proinflammatory mediators such as prostaglandin D2, LTs, cytokines, and chemokines [18e21]. These mediators have been postulated to be responsible for airway inflammation and remodeling in allergic asthma [19, 22] .
Although 20(S)-dihydroprotopanaxadiol and 20(S)-dihydroprotopanaxatriol have distinctive immunological responses [23, 24] , the effects of 20(S)-protopanaxatriol (PPT, Fig. 1A) , one of the ginseng saponin metabolites formed by human intestinal bacteria, on the inflammatory mediator release during mast cell activation, which is a well-known event in allergic asthma, has not been reported yet. Therefore, we examined the effects of PPT on the release of inflammatory mediators from the guinea pig lung mast cells (GPMCs) and mouse bone marrow-derived mast cells (BMMCs) activated by a specific antigen/antibody reaction to determine the role of ginseng intestinal metabolites of orally administered ginseng extract.
Materials and methods

Animals
Female Hartley guinea pigs weighing 200e250 g and female BALB/c mice weighing 20 g (age 8 weeks) were purchased from Samtako BioKorea (Osan, Korea) and maintained in specific Expressions of cytokine mRNA in activated BMMCs. The total number of experiments were eight (n ¼ 8). ***, p < 0.001 versus control (Con); þ p < 0.05; þþþ p < 0.05 versus OVA challenge. 1) Numbers below the bands indicate the ratio of band intensity of each band versus that of control and GAPDH mRNA.
pathogen-free conditions prior to being sacrificed. All animals were housed in accordance with the guideline from the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC), and all protocols were approved by the Institutional Review Board and conducted in the Laboratory Animal Research Center of Sungkyunkwan University, Suwon, Korea.
Reagents
OVA (fraction V), collagenase (type I), elastase (type I, porcine pancreatic), human serum albuminedintrophenyl (HSA-DNP), Fluo-3 AM, and percoll were purchased from Sigma-Aldrich Chemical Co (St Louis, MO, USA); leukotriene immunoassay kit and [ 3 H]arachidonic acid were purchased from PerkinElmer (Waltham, MA, USA); and gelatin was purchased from Difco Laboratories (Detroit, MI, USA). PPT (molecular weight, 476.7) was prepared by the chemical modification of ginseng saponin with periodic acid as described previously [25] . Its structure is shown in Fig. 1A . Other chemicals and reagents used in this experiment were of the best grade.
The PPT was dissolved in 50mM stock solution in dimethyl sulfoxide (DMSO), and diluted prior to use. The percentage (%) of DMSO in experimental solution or media was 0.01%, 0.02%, and 0.04% for 10mM, 50mM, or 100mM PPT, respectively. These percentages of DMSO did not affect release of mediators (data not shown). The concentration of PPT was chosen in preliminary experiments.
Immunization and preparation of anti-OVA antibody
Ten outbred female guinea pigs were immunized by injecting a mixture of 50 mg/200 mL OVA and complete Freund's adjuvant into a foot pad. After 1 week, 100 mg/200 mL OVA was injected intradermally at one side of the back of the animals and 200 mg/200 mL of OVA at the other side of the back of the animals. One week later, mice were sacrificed for getting sera, and the sera were kept in aliquots at À70 C until use [26] . To separate IgG1 antibody from sera, guinea pig serum was applied to anti-IgG 2 affinity column and the column was washed with 0.1M citric acid (pH 2.1). IgG 1 passed through and it was concentrated under pressure for the experiment. The titers of anti-OVA antibody were in the range 1,600e 3,200 using passive cutaneous anaphylaxis method [26] . The sera were used for preparing the sensitized GPMCs.
GPMC preparation
GPMCs were isolated and purified as reported previously [26] . Briefly, each lung isolated from eight unsensitized guinea pigs was perfused with 50 mL of the modified Tyrode's buffer (TGCM buffer: 137mM NaCl, 0.36mM NaH 2 PO 4 , 2.6mM KCl, 1mM CaCl 2 , 1.5mM MgCl 2 , 119mM NaHCO 3 , 5.5mM glucose, 1 g/L gelatin, pH 7.4). After removing large airways and blood vessels, the lungs were chopped with a McIlwain tissue chopper (The Mickle Laboratory Engineering Co., Gomshall, Surrey, UK). Pooled tissue was treated three times with collagenase (125 U/g tissue) and elastase (5 U/g tissue) for 15 min, 15 min, and 25 min. The freed cells were separated by filtrating through mesh and Nytex mesh (100 mm). The cells were washed with Tyrode's buffer without CaCl 2 and MgCl 2 containing gelatin (TG buffer) and laid over gradients consisting of 10 mL Percoll (density, 1.045 g/mL), and then centrifuged at 800 Â g for 20 min. Pelleted cells containing mast cells (w3.5 Â 10 8 cells/ gradient) were resuspended in TG buffer and applied in discontinuous Percoll (1 mL) density gradients (density gradients: 1.06 g/ mL, 1.07 g/mL, 1.08 g/mL, 1.09 g/mL, and 1.10 g/mL) for centrifugation at 800 Â g for 20 min. The mast cells were collected with the highest purity and number (1e2 Â 10 7 ) from the bands between the 1.09 g/mL and 1.10 g/mL densities. This gradient band was removed, washed with TGCM buffer. The partially purified mast cells were identified with Alcian blue staining, and the viability was assessed using trypan blue exclusion assay. The purity of the mast cell preparation was 80e90% and the cell viability was consistently > 98%.
Culture of BMMCs
Bone marrow cells were flushed from femurs and tibias of BALB/ c mice. RBC was lysed using 0.1M NH 4 Cl and remaining cells were washed, resuspended, and cultured for 5 weeks in RPMI-1640 supplemented with 10% heat-inactivated fetal bovine serum and 50% WEHI-3B conditioned media, which contains interleukin (IL)-3. The media were changed twice per week. BMMCs were confirmed by May-Grünwald Giemsa staining [27] . Briefly, BMMCs were collected onto object glasses by cytospin (400 Â g, 3 min). Cells were fixed in methanol for 2e3 min and then stained with MayGrünwald solution for 15 min, followed by Giemsa solution for 10 min and by washing steps in H 2 O. The purity of BMMCs was > 99%.
2.6. Sensitization and measurements of mediator release in the activated mast cells As described previously [26] , the partially purified GPMCs (4 Â 10 5 ) were sensitized with anti-OVA antibody (1 Â 10 6 cells/mL antibody) for 45 min at 37 C in a shaking water bath. The cells were then washed, suspended in TGCM buffer, and challenged with 1.0 mg/mL OVA for 10 min or 20 min for histamine and LT release, respectively. After terminating the reaction on ice bath, supernatant was taken for measuring the amounts of the released histamine and LTs. BMMCs (1 Â 10 6 cells) were sensitized with anti-DNP IgE antibody (0.1 mg/mL) overnight at 37 C. The cells were washed, and then challenged with 1.0 ng/mL HSA-NP) for time periods indicated (optimal time, 6 h) at 37 C in Tyrode's buffer [27] .
In all experiments, optimal time and concentration for activation of GPMCs and BMMCs were first determined in preliminary experiments, and both types of mast cells were treated with PPT (10mM, 50mM, or 100mM) 5 min prior to the antigen challenge.
Histamine assay
Amounts of histamine release in each supernatant obtained after activation of GPMCs or BMMCs were quantified by the automated fluorometric analyzer (with dialysis; Series 300 Analyzer; Astoria Clackamas, OR, USA). The detection limit of this assay is approximately 5 ng/mL of histamine. Amounts of histamine release were expressed as the percentage of the total histamine in nonstimulated cells [26] .
LT immunoassay
The amounts of LTs in each supernatant obtained from GPMCs or BMMCs were determined using an enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer's instructions. Briefly, 50 mL samples were incubated with anti-LT antiserum (diluted 1:120) and acetylcholinesterase-linked LTs (diluted 1:120) in wells that were coated with mouse monoclonal antibodies for 18 h at room temperature. After rinsing with washing buffer, color was developed using Ellman's reagent, and the plates were read at 412 nm with a spectrophotometer. The concentrations of LTs were then calculated using standard curves generated with specific LTs standards and using analysis tools on the Cayman Chemical website (http://www.caymanchem.com/ app/template/analysis%2CEIA.vm/a/z).
Reverse transcriptionepolymerase chain reaction
Total cellular RNA was isolated from BMMCs (1 Â 10 6 cells) using ] i of both types of mast cells were monitored for 10 min after each antigen stimulation using a confocal laser scanning microscopy (Leica TCS NT Confocal Microscopy, Leica, Heidelberg, Germany) [24, 26] . [Ca 2þ ] i was estimated with LSM500 software (Mitutoyo America Corporation, Aurora, IL, USA). Relative intensity (RI) indicated the ratio of optical fluorescence density versus the control (RI ¼ 1).
Immunoprecipitation for Syk
Immunoprecipitation of Syk protein was performed according to method provided previously [29] . Briefly, agarose conjugate (50 mL) was washed twice with washing buffer (PBS, pH 7.4), centrifuged for 10 s at 12,000 Â g at room temperature and then resuspended in washing buffer. Agarose conjugate was added to 10 ml anti-Syk antibody (Upstate, Lake Placid, NY, USA), incubated for 60 min at room temperature with gentle mixing, and then centrifuged at 3,000 Â g for 2 min at 4 C. Samples were washed with 1 mL washing buffer, centrifuged at 3,000 Â g for 2 min at 4 C, and this step was repeated at least twice. Cell lysates (200 mg protein) were added to agarose conjugate-bound antibody, and incubated overnight at 4 C with gentle mixing. Immunoprecipitated complexes were washed with washing buffer and centrifuged at 3,000 Â g for 2 min at 4 C. Pellets were washed with 1 mL washing buffer and centrifuged at 3,000 Â g for 2 min at 4 C. This step was repeated at least three times. The pellet was resuspended with 25e 100 mL Laemmli sample buffer [0.125M Tris HCl (pH 6.8), 4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% bromphenol blue]. Samples were heated at 95 C for 5 min, centrifuged for 30 s at 12,000 Â g at room temperature, and then the supernatants collected (immunoprecipitation sample).
Immunoprecipitation samples were stored in sample buffer at À70 C until assay. Samples and molecular weight standards were run with known concentrations on sodium dodecyl sulfatee polyacrylamide gel electrophoresis, transferred to nitrocellulose membrane, and immunoblotting performed.
Measurements of protein kinase C activity in the activated GPMCs
The sensitized GPMCs (1 Â 10 6 cells) were preincubated in the presence of histone (0.2 mg/mL), phosphatidylserine (40 mg/mL),
and [g- 
Immunoblotting for signaling molecules in the activated mast cells
The MgCl 2 , 0.2mM EDTA, 0.5mM DTT, 25% glycerol, 0.2mM PMSF, 1 mg/ mL leupeptin, and 1 mg/mL aprotinin). After incubation at 4 C for 20 min on a shaking platform, the nuclei were clarified by centrifugation at 15,000 Â g for 10 min. The supernatant (nuclear extract) was then transferred to a new tube and quantified using Bradford's method. Nuclear extracts were stored at À70 C until required [28] .
Ten microliters of a mixture of NF-kB (5 0 -AGT TGA GGG GAC TTT CCC AGG C-3 0 , 3 0 -TCA ACT CCC CTG AAA GGG TCC G-5 0 ) or activator protein-1 (AP-1; 5 0 -CGC TTG ATG AGT CAG CCG GAA-3 0 , 3 0 -GCG AAC TAC TCA GTC GGC CTT-5 0 ) oligonucleotide (1.75mM), T4 polynucleotide kinase 10 Â buffer, [a-32 P]ATP (10 mCi; 3,000 Ci/mmol), nuclease-free water, and T4 polynucleotide kinase (5e10 U/mL) were incubated at 37 C for 30 min. The reaction was stopped by adding 1 mL EDTA (0.5M). After adding 89 mL Tris-EDTA buffer (10mM Tris-HCl pH 8.0, 1mM EDTA), unincorporated nucleotides were separated from the DNA probe by G-25 spin column chromatography. The nuclear extract and gel shift binding 5 Â buffer [20% glycerol, 5mM MgCl 2 , 2.5mM EDTA, 2.5mM DTT, 250mM NaCl, 50mM Tris-HCl pH 7.5, and 0.25 mg/mL poly(dI-dC)] were incubated at room temperature for 10 min, and then 20e30 fmol of 32 Plabeled NF-kB or AP-1 oligonucleotide was added and incubated at room temperature for 20 min. After stopping the reaction, 1 mL of 10 Â gel loading buffer was added to each reaction. Reaction mixtures were electrophoresed on 6% polyacrylamide gels, and the gels were analyzed using FLA-2000 (Fujifilm, Tokyo, Japan).
Statistical analysis
Experimental data were expressed as mean AE standard error of the mean. An analysis of variance (ANOVA) was used for statistical analysis. Significance between control and experimental groups was determined by Scheffe's posthoc test using SPSS version 21 (SPSS Inc., Chicago, IL, USA). The bands for RT-PCR, western blot and electrophoretic mobility shift assay are representative of four independent experiment (n ¼ 4). A p value of 0.05 was regarded as statistically significant.
Results
Effect of PPT on the release of histamine and LTs in the activated GPMCs and BMMCs
It is well known that histamine and LTs are released from mast cells when activated by antigen/antibody reaction. Two types of mast cells, GPMCs and mouse bone marrow-derived mast cells BMMCs were used for this study since commercially available antibodies for guinea pigs have certain limitations for investigating signaling molecules related to allergic responses. In addition, it is known that mast cells are different in their function, depending on their location in the types of organs (lung, bone marrow, etc.) and species (guinea pigs, mice, etc.).
In order to determine whether PPT causes some effects on the release of inflammatory mediators (histamine and LTs) in quiescent GPMCs or BMMCs, unsensitized each types of mast cells pretreated with various concentrations of PPT (5mM, 10mM, 50mM, 100mM, or 300mM) for 5 min were challenged by OVA (1.0 mg/mL), or both types of mast cells sensitized with anti-OVA antibody were challenged with various concentrations of PPT (5mM, 10mM, 50mM, 100mM, or 300mM) for 30 min or 1 h. It was confirmed that PPT itself did not cause any effects on the mediator releases if not antigen/antibody stimulation (data not shown).
Effects of PPT on the mediator release were examined in GPMCs or BMMCs activated by each specific antigen/antibody reaction. In the activated GPMCs, PPT pretreatment (10mM, 50mM, or 100mM) dose-dependently inhibited histamine release by 5.4%, 41.4%, and 60.5%, respectively (28.6 AE 0.05% for 10mM; 17.7 AE 0.34% for 50mM; and 11.9 AE 0.25% for 100mM PPT), compared with that of OVA stimulation (30.2 AE 0.72%; Fig. 1B, left panel) . In the activated BMMCs, histamine release was inhibited by PPT pretreatment by 7.9%, 37.6%, and 70.1% (30.6 AE 0.07% for 10mM; 20.7 AE 0.35% for 50mM; and 9.9 AE 0.26% for 100mM PPT), compared with that of OVA challenge (33.2 AE 0.76%; Fig. 1B, right panel) .
Patterns of LT secretion in the activated GPMCs or BMMCs were similar to those of histamine release in both types of mast cells. PPT (10mM, 50mM, or 100mM) inhibited LTs release by 3.4%, 27.6% and 55.4%, respectively, in activated GPMCs (6.5 AE 0.04 Â 
Effect of PPT on the expressions of cytokine mRNA in activated BMMCs
In addition to the release of histamine and LTs, mast cells secrete various types of cytokines, particularly inflammatory cytokines (IL1b, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, TNF-a, and interferon-g) [20] . Thus, whether the mRNA levels of each cytokines were altered by PPT was examined in the activated BMMCs. PPT pretreatment (10mM, 50mM, or 100mM) inhibited the expressions of all cytokines' mRNA in dose-dependent manner, except IL-10 mRNA expression, which was increased in the activated BMMCs (Fig. 1C) . ities of PKC and PLA 2 in GPMCs were tested only at the highest concentration of PPT since it was hard to purify GPMCs and thus only limited GPMCs were available.
Effect of PPT on the expression of Syk protein in the activated BMMCs
As PPT reduced the [Ca 2þ ] i elevated in IgE-induced mast cell activation, it was examined whether Syk kinase, an upstream signaling molecule of [Ca 2þ ] i influx was affected by PPT pretreatment. PPT (10mM, 50mM, or 100mM) significantly reduced the increased level of expression of Syk kinase in BMMCs when activated by antigen/antibody stimulation (Fig. 2C) .
Effect of PPT on the PKC activity in the activated GPMCs and BMMCs
It has been reported that PKC is activated by an elevation of [Ca 2þ ] i level in the stimulated B cells and mast cells [26, 31] . The changes in the PKC activity in both types of mast cells were measured after stimulation. The activity of PKC was enhanced in OVA-challenged GPMCs by 59.3%. The OVA-induced increment in PKC activity was remarkably counteracted by 100mM PPT (Fig. 3A) . The Ca 2þ -dependent PKC isoforms (PKCa, bI, and bII) are activated in mast cells, and then the activated PKC isoforms regulate mitogen-activated protein (MAP) kinases [18, 33] . Fig. 3B showed that PKC isoforms (a, bI, bII) are phosphorylated by antigen/antibody reaction in BMMCs, and PPT (10mM, 50mM, or 100mM) inhibited the phosphorylation of PKC isoforms in the activated BMMCs. In addition, we observed the phosphorylations of ERK, JNK, and p38 MAP kinases in activated BMMCs. PPT (10mM, 50mM, or 100mM) reduced the augmented phosphorylation of MAP kinases in activated BMMCs (Fig. 3C ).
Effect of PPT on the PLA 2 activity in activated GPMCs and BMMCs
The changes in the PLA 2 activity in GPMCs were assayed after OVA stimulation. OVA increased the PLA 2 activity by 38% of basal activity in stimulated GPMCs. The OVA-induced increment in the enzyme activity was decreased by 30.2% when the cells were pretreated with 100mM PPT (Fig. 4A) .
In GPMCs and BMMCs, the level of protein expression of PLA 2 was enhanced upon stimulation with OVA challenge (Fig. 4B) . PPT pretreatment (10mM, 50mM, or 100mM) dose-dependently reduced the PLA 2 expression in each type of activated mast cells.
Effect of PPT on the activity of COX-1/2 in the activated BMMCs
It is well known that prostaglandins (PGs) are produced by the actions of both constitutive enzyme COX-1 and inducible enzyme COX-2. In mast cells, certain amount of COX-1 is expressed and COX-2 is induced by the antigen/antibody stimulation [34, 35] . It was also observed that expression of COX-2 was enhanced in activated BMMCs, but COX-1 was not affected (Fig. 4C) . PPT decreased dose-dependently only the induced level of COX-2 expression by antigen stimulation, but not that of COX-1 expression (Fig. 4C) .
Effect of PPT on the activity of transcription factors in the activated BMMCs
NF-kB and AP-1 are transcription factors controlling the expressions of inflammatory cytokines in mast cells. These transcription factors were upregulated in the activated BMMCs. PPT (10mM, 50mM, or 100mM) inhibited the DNA binding activities of transcription factors in a dose-dependent manner (Fig. 4D ).
Discussion
Mast cells participate in the induction of innate and adaptive immune responses [20, 36] . Mast cells influence both health and diseases, such as allergy, arthritis, autoimmunity, and neoplasia, by releasing and producing a variety of mediators [20, 26] . Ginsenosides and ginsan, the major active saponin and polysaccharide components of ginseng, respectively, have many biological activities including inflammatory responses in mast cells as well as allergic inflammation [7, 16, 37] . Herein, we demonstrated that PPT, one of the ginseng saponin metabolites formed by human intestinal bacteria and of nonsugar moiety of ginsenoside (aglycone), reduced the release of mediators by [Ca 2þ ] i level, PLA 2 , PKC, and NF-kB/AP-1 activities which are downstream signals regulated by Syk kinase in FceRI-mediated mast cell activation. The antigen-mediated activation of mast cells via engagement of the IgE bound to FceRI receptor represents an initial event in the development of type I hypersensitivity reaction, and results in degranulation, with the release of various inflammatory mediators, such as histamine, LTs, and cytokines [20, 26, 32] . That is, IgE-mediated signaling pathways lead to the release of preformed mediators (histamine, tryptase, etc.) by PKC activity that is accompanied by Ca 2þ influx, which is critical for the downstream propagation signals by Syk-mediated phosphorylation and the activation of PLCg or PLD enzyme [18, 20, 38, 39] . Therefore, we examined the effects of PPT on the well-known signaling pathways in mediator release from IgE-mediated mast cell activation. Our data (Figs. 1B, 2 , 3A, 3B) suggest that PPT reduces histamine release via the inhibition of PKC activity caused by blocking of the rise in [Ca 2þ ] i through regulating Syk in FceRImediated mast cell activations. Similarly, it was reported that ginsenoside Rb1, which has a sugar moiety in its structure, inhibited mediator release in activated GPMCs [9] . However, there has been a report that ginseng saponin enhanced [Ca 2þ ] i and PKC activity in macrophage activation [6] . This may be due to the cell types or the sort of ginsenoside components used in each separate experiment. Rapid hydrolysis of phospholipids in mast cell membrane also occurs through the activation of cytosolic phospholipase A 2 (cPLA 2 ) in IgE-mediated signaling pathways. Hydrolyzed phospholipids were converted into arachidonic acids. Then, enzymes such as COX-1/2 or 5-lipoxigenase (LOX) convert them into PGs and LTs, respectively, which affects the early phase of allergic responses in mast cells [34, 35, 38, 40, 41] . A rise in [Ca 2þ ] i is necessary for translocation of cPLA 2 to the cell membrane in FceRI-mediated mast cell activation [18, 42] . It has been reported that ginsenoside Rh1 inhibited COX-2 [7] . Our data (Figs. 1B, 2A , 2B, 4AeC) suggest that PPT-mediated reduction in [Ca 2þ ] i leads to the decrements in production of LTs via inhibiting the activities of cPLA 2 and most likely LOX during mast cell activations. In addition, we observed that PPT causes reduction of COX-1/2 expression, which may result in PG production in combination with the inhibition of PLA 2 activity and the reduction of [Ca 2þ ] i . This indicates that PPT may concurrently inhibit the COX-2 and LOX activities, thereby reducing early phase of allergic responses. IgE-mediated signaling pathways induce production of inflammatory cytokines via activation of MAP kinases during activation of mast cells [32, 43, 44] . NF-kB and AP-1 are pleiotropic transcription factors that play an important role in regulating the expression of multiple genes including Th2 cytokines [20] , and allergic inflammation is associated with increased NF-kB activity in animal lung tissues and BAL cells [28, 45] . A rise of [Ca 2þ ] i level also leads to the activation of MAP kinases and NF-kB, which play important roles in the control of IgE-mediated cytokine synthesis in mast cells [46e 49]. Our results (Figs. 1C, 2 , 3C, 4D) suggest that PPT inhibits production of inflammatory cytokines via inhibiting an increase of cellular Ca 2þ level, the activities of MAP kinases and NF-kB/AP-1 in the IgE-mediated activated mast cells. Similarly, ginsenosides have been reported to inhibit NF-kB activation as well as histamine release in certain cell lines [7, 37] . However, IL-10, which is known as an anti-inflammatory cytokine, was not inhibited in the PPT pretreatment.
PPT pretreatment exerted antiallergic effects in the same manner in both types of mast cells when activated by specific antigen/antibody reaction. It competition. The data are representative of four independent experiments (n ¼ 4). HSA-DNP, human serum albuminedinitrophenyl.
